Enlivex Therapeutics Ltd (ENLV)

$1.15 +0.11 (10.58%)
Market Cap 239.76M
Revenue (ttm) 0.00
Net Income (ttm) -15.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 855,299
Avg Vol 487,302
Day's Range N/A - N/A
Shares Out 237.38M
Stochastic %K 21%
Beta 1.63
Analysts Sell
Price Target $13.00

Company Profile

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis pat...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 2 620 8072
Address:
14 Einstein Street, Ness Ziona, Israel
Nicks_pics
Nicks_pics Jul. 14 at 2:12 PM
$ENLV My shares are marked safe ✅ from panic selling.
1 · Reply
FST3
FST3 Jul. 14 at 1:40 PM
$ENLV - wow $30K of shares sales $15M in market value, do people really think that the FDA would provide a RMAT designation without any evidence that allocetra doesn't meet an unmet need? Playing with fire.
0 · Reply
jacksonjohn750
jacksonjohn750 Jul. 13 at 4:27 PM
$ENLV s-c AM likely
0 · Reply
FST3
FST3 Jul. 13 at 1:37 PM
$ENLV the shorts have to cover, not looking good for them. The FDA RMAT designation speaks volumes
0 · Reply
notreload_ai
notreload_ai Jul. 13 at 1:35 PM
$ENLV receives FDA RMAT designation for Allocetra, its investigational therapy for age-related knee osteoarthritis. Phase IIb trial now underway with first U.S. patient dosed. https://notreload.xyz/xy/enlivex-secures-fda-rmat-designation-for-allocetra-in-knee-oa/
1 · Reply
Stock_Catcher
Stock_Catcher Jul. 13 at 12:01 PM
$ENLV Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
0 · Reply
JJRADANO
JJRADANO Jul. 10 at 4:32 PM
$ENLV Same with RBNE. Total manipulation and corruption. Small fry don't stand a chance.
1 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Jul. 9 at 11:19 PM
$WNW $OPEN $ENLV going to $300 $ARAI VSEE
0 · Reply
GregGregor7369
GregGregor7369 Jul. 9 at 3:41 PM
$ENLV GRRRRRRrrrrrrrrrrrrrrr...stock price manipulation...
0 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Jul. 9 at 3:27 PM
$VSEE $JLHL $ENLV VSEE next
0 · Reply
Latest News on ENLV
Enlivex Therapeutics receives RMAT designation for Allocetra from FDA

2026-07-13T12:26:09.000Z - 1 day ago

Enlivex Therapeutics receives RMAT designation for Allocetra from FDA

Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis

Jul 13, 2026, 8:00 AM EDT - 1 day ago

Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis

Enlivex Therapeutics trading halted, news pending

2026-07-08T23:50:17.000Z - 5 days ago

Enlivex Therapeutics trading halted, news pending

Enlivex Therapeutics announces 1-for-15 reverse split

2026-07-07T12:36:17.000Z - 7 days ago

Enlivex Therapeutics announces 1-for-15 reverse split

Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026

Jul 7, 2026, 8:00 AM EDT - 7 days ago

Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume

Jun 24, 2026, 8:00 AM EDT - 20 days ago

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume

Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion

Jun 22, 2026, 8:45 AM EDT - 22 days ago

Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion

Enlivex Therapeutics announces issuance of Australian patent

2026-06-15T13:01:02.000Z - 4 weeks ago

Enlivex Therapeutics announces issuance of Australian patent

Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis

Jun 15, 2026, 8:00 AM EDT - 4 weeks ago

Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis

ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026

Jun 2, 2026, 8:00 AM EDT - 6 weeks ago

ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026

Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026

Jun 1, 2026, 8:00 AM EDT - 6 weeks ago

Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026

Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board

May 28, 2026, 8:00 AM EDT - 6 weeks ago

Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board

Enlivex comments on $100M commitment to Rain’s prediction market

2026-05-27T15:37:44.000Z - 6 weeks ago

Enlivex comments on $100M commitment to Rain’s prediction market

Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity

May 27, 2026, 8:00 AM EDT - 6 weeks ago

Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity

Enlivex Therapeutics doses first patient in Allocetra trial

2026-05-18T12:17:18.000Z - 2 months ago

Enlivex Therapeutics doses first patient in Allocetra trial

Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

May 18, 2026, 8:00 AM EDT - 2 months ago

Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification

May 15, 2026, 4:10 PM EDT - 2 months ago

Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange

Apr 30, 2026, 8:30 AM EDT - 2 months ago

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange

Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million

Apr 28, 2026, 8:30 AM EDT - 2 months ago

Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million

Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress

Apr 23, 2026, 8:30 AM EDT - 2 months ago

Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress

Enlivex Therapeutics files to sell 23.33M ordinary shares for holders

2026-04-21T20:54:59.000Z - 2 months ago

Enlivex Therapeutics files to sell 23.33M ordinary shares for holders

Enlivex receives CTA approval by DKMA for Phase 2b trial of Allocetra

2026-04-21T12:58:15.000Z - 3 months ago

Enlivex receives CTA approval by DKMA for Phase 2b trial of Allocetra

Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

Apr 21, 2026, 8:30 AM EDT - 3 months ago

Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

Enlivex Registration statement: Registration filing

Apr 21, 2026, 8:00 AM EDT - 3 months ago

Enlivex Registration statement: Registration filing

Ondo Global Markets Tokenizes Enlivex's Ordinary Shares

Apr 8, 2026, 8:30 AM EDT - 3 months ago

Ondo Global Markets Tokenizes Enlivex's Ordinary Shares

Enlivex Therapeutics price target raised to $20 from $13 at H.C. Wainwright

2026-04-07T10:07:47.000Z - 3 months ago

Enlivex Therapeutics price target raised to $20 from $13 at H.C. Wainwright

Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt

Mar 26, 2026, 8:30 AM EDT - 3 months ago

Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt

Enlivex Earnings Call Transcript: Q4 2025

Mar 25, 2026, 9:00 AM EDT - 3 months ago

Enlivex Earnings Call Transcript: Q4 2025

Enlivex Annual report: Q4 2025

Mar 25, 2026, 9:00 AM EDT - 3 months ago

Enlivex Annual report: Q4 2025

Enlivex Quarterly report: Q4 2025

Mar 25, 2026, 9:00 AM EDT - 3 months ago

Enlivex Quarterly report: Q4 2025

Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48

Mar 25, 2026, 8:30 AM EDT - 3 months ago

Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48

Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program

Mar 24, 2026, 8:30 AM EDT - 4 months ago

Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program

Enlivex Slides: Investor presentation

Mar 24, 2026, 8:00 AM EDT - 4 months ago

Enlivex Slides: Investor presentation

Enlivex Therapeutics announces FDA clearance of Allocetra new drug application

2026-03-23T12:21:45.000Z - 4 months ago

Enlivex Therapeutics announces FDA clearance of Allocetra new drug application

Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

Mar 23, 2026, 8:00 AM EDT - 4 months ago

Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

Enlivex Therapeutics management to meet virtually with BTIG

2026-02-18T17:40:32.000Z - 5 months ago

Enlivex Therapeutics management to meet virtually with BTIG

Enlivex Therapeutics announces new listing of RAIN token on Kraken

2026-02-10T13:11:38.000Z - 5 months ago

Enlivex Therapeutics announces new listing of RAIN token on Kraken

Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange

Feb 10, 2026, 8:00 AM EST - 5 months ago

Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange

Enlivex Therapeutics announces listing of RAIN token on WhiteBIT

2026-01-26T13:11:08.000Z - 6 months ago

Enlivex Therapeutics announces listing of RAIN token on WhiteBIT

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange

Jan 26, 2026, 8:00 AM EST - 6 months ago

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange

Enlivex Therapeutics shares to trade exclusively on Nasdaq

2026-01-23T13:05:21.000Z - 6 months ago

Enlivex Therapeutics shares to trade exclusively on Nasdaq

Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq

Jan 23, 2026, 8:00 AM EST - 6 months ago

Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq

Enlivex Therapeutics price target raised to $13 from $7 at H.C. Wainwright

2026-01-12T11:10:08.000Z - 6 months ago

Enlivex Therapeutics price target raised to $13 from $7 at H.C. Wainwright

Enlivex says RAIN token listed on KuCoin crypto exchange

2026-01-07T13:28:01.000Z - 6 months ago

Enlivex says RAIN token listed on KuCoin crypto exchange

Enlivex Therapeutics files to sell 212M ordinary shares for holders

2025-12-23T21:40:13.000Z - 7 months ago

Enlivex Therapeutics files to sell 212M ordinary shares for holders

Enlivex Registration statement: Registration Filing

Dec 23, 2025, 7:00 AM EST - 7 months ago

Enlivex Registration statement: Registration Filing

Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development

Dec 4, 2025, 8:00 AM EST - 7 months ago

Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development

Enlivex Therapeutics closes $212M private placement

2025-11-26T13:10:18.000Z - 8 months ago

Enlivex Therapeutics closes $212M private placement

Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors

Nov 24, 2025, 10:00 AM EST - 8 months ago

Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors

Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

Nov 24, 2025, 7:55 AM EST - 8 months ago

Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis

Nov 24, 2025, 6:40 AM EST - 8 months ago

Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Quarterly report: Q3 2025

Nov 14, 2025, 4:00 PM EST - 8 months ago

Enlivex Quarterly report: Q3 2025

Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025

Oct 28, 2025, 8:15 AM EDT - 9 months ago

Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025

D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

Sep 29, 2025, 8:15 AM EDT - 10 months ago

D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results

Sep 11, 2025, 8:00 AM EDT - 10 months ago

Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results

Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Sep 9, 2025, 8:00 AM EDT - 11 months ago

Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Enlivex Quarterly report: Q2 2025

Aug 29, 2025, 4:00 PM EDT - 11 months ago

Enlivex Quarterly report: Q2 2025

Enlivex Transcript: Status Update

Aug 18, 2025, 8:00 AM EDT - 11 months ago

Enlivex Transcript: Status Update

Enlivex Press release: Status Update

Aug 18, 2025, 8:00 AM EDT - 11 months ago

Enlivex Press release: Status Update

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

Aug 18, 2025, 7:45 AM EDT - 11 months ago

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar

Aug 14, 2025, 8:30 AM EDT - 11 months ago

Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

Jul 28, 2025, 8:30 AM EDT - 1 year ago

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

Jun 10, 2025, 8:30 AM EDT - 1 year ago

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

Enlivex Slides: Company Presentation

Jun 3, 2025, 6:00 PM EDT - 1 year ago

Enlivex Slides: Company Presentation

Enlivex Earnings release: Q1 2025

May 29, 2025, 6:00 PM EDT - 1 year ago

Enlivex Earnings release: Q1 2025

Enlivex Selected to Present at Israeli BioMed 2025 Conference

May 20, 2025, 8:00 AM EDT - 1 year ago

Enlivex Selected to Present at Israeli BioMed 2025 Conference

Enlivex Registration statement: Registration Filing

May 2, 2025, 8:00 AM EDT - 1 year ago

Enlivex Registration statement: Registration Filing

Enlivex Annual report: Q4 2024

Apr 29, 2025, 6:00 PM EDT - 1 year ago

Enlivex Annual report: Q4 2024

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress

Apr 23, 2025, 8:30 AM EDT - 1 year ago

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

Apr 21, 2025, 8:30 AM EDT - 1 year ago

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Enlivex Slides: Company Presentation

Mar 6, 2025, 7:00 AM EST - 1 year ago

Enlivex Slides: Company Presentation

Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis

Mar 4, 2025, 4:30 PM EST - 1 year ago

Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis

Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis

Mar 3, 2025, 8:22 AM EST - 1 year ago

Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Issues Urgent Statement on Fraudulent News Dissemination

Feb 18, 2025, 6:20 AM EST - 1 year ago

Enlivex Issues Urgent Statement on Fraudulent News Dissemination

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jan 10, 2025, 9:00 AM EST - 1 year ago

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIAF

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Dec 11, 2024, 8:30 AM EST - 1 year ago

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Dec 5, 2024, 10:49 AM EST - 1 year ago

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Quarterly report: Q3 2024

Nov 28, 2024, 6:00 PM EST - 1 year ago

Enlivex Quarterly report: Q3 2024

Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

Nov 26, 2024, 10:15 AM EST - 1 year ago

Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Nov 14, 2024, 8:00 AM EST - 1 year ago

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis

Oct 30, 2024, 8:00 AM EDT - 1 year ago

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis

Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Sep 24, 2024, 8:30 AM EDT - 1 year ago

Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Nicks_pics
Nicks_pics Jul. 14 at 2:12 PM
$ENLV My shares are marked safe ✅ from panic selling.
1 · Reply
FST3
FST3 Jul. 14 at 1:40 PM
$ENLV - wow $30K of shares sales $15M in market value, do people really think that the FDA would provide a RMAT designation without any evidence that allocetra doesn't meet an unmet need? Playing with fire.
0 · Reply
jacksonjohn750
jacksonjohn750 Jul. 13 at 4:27 PM
$ENLV s-c AM likely
0 · Reply
FST3
FST3 Jul. 13 at 1:37 PM
$ENLV the shorts have to cover, not looking good for them. The FDA RMAT designation speaks volumes
0 · Reply
notreload_ai
notreload_ai Jul. 13 at 1:35 PM
$ENLV receives FDA RMAT designation for Allocetra, its investigational therapy for age-related knee osteoarthritis. Phase IIb trial now underway with first U.S. patient dosed. https://notreload.xyz/xy/enlivex-secures-fda-rmat-designation-for-allocetra-in-knee-oa/
1 · Reply
Stock_Catcher
Stock_Catcher Jul. 13 at 12:01 PM
$ENLV Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
0 · Reply
JJRADANO
JJRADANO Jul. 10 at 4:32 PM
$ENLV Same with RBNE. Total manipulation and corruption. Small fry don't stand a chance.
1 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Jul. 9 at 11:19 PM
$WNW $OPEN $ENLV going to $300 $ARAI VSEE
0 · Reply
GregGregor7369
GregGregor7369 Jul. 9 at 3:41 PM
$ENLV GRRRRRRrrrrrrrrrrrrrrr...stock price manipulation...
0 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Jul. 9 at 3:27 PM
$VSEE $JLHL $ENLV VSEE next
0 · Reply
TwongStocks
TwongStocks Jul. 9 at 11:33 AM
$ENLV $RBNE Both with reverse splits today, full details in the quoted post. Trading will resume at 9:00am ET with the RS in effect.
1 · Reply
FreeBeerTomorrow
FreeBeerTomorrow Jul. 9 at 7:21 AM
$ENLV ENLV (Enlivex Ltd.) is executing a 1-for-15 reverse stock split today, Thursday, July 9, 2026. With an outstanding share count of just 16.8M, the tradeable float is bound to be a micro-cap low-float runner territory (likely somewhere between 2.3M and 3.9M shares).
0 · Reply
TwongStocks
TwongStocks Jul. 8 at 8:55 PM
Two NASDAQ stocks with reverse splits on Thursday. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am ET Thursday morning. $ENLV 1 for 15. Will reduce outstanding shares from approx 252.48m to approx 16.83m. $RBNE 1 for 15. Will reduce outstanding shares from approx 8.7m to approx 580k.
0 · Reply
ajmrtxl
ajmrtxl Jul. 8 at 3:53 PM
$ENLV 's latest data on SqueezeFinder
0 · Reply
FST3
FST3 Jul. 8 at 2:02 PM
$ENLV people make nonsensical decisions, 150K in shares sold wiping off $10M in market share, when there are over 220M shares outstanding. It tells you that this movement is temporary and BS. Being fearful leads to silly mistakes.
1 · Reply
GolfAndStockzz
GolfAndStockzz Jul. 8 at 1:37 PM
$ENLV not going to lie, I’m starting to get nervous their is negative enthusiasm for this company…
1 · Reply
jpoong
jpoong Jul. 8 at 4:17 AM
$ENLV I hope Bryan Johnson tries Allocetra.
1 · Reply
EML33
EML33 Jul. 8 at 3:35 AM
$ENLV to sell or not to sell tomorrow, down 10k don’t want to loose it all ?!?!
1 · Reply
Nicks_pics
Nicks_pics Jul. 8 at 12:20 AM
$ENLV Allocetra while still in clinical trials, appears to successfully modulate an overreacting immune system back to homeostasis. The company is funded and the management team experienced. Treatment for knee osteoarthritis is a huge TAM in people over 65. Once approved other applications will be pursued with vigor.
1 · Reply
TwongStocks
TwongStocks Jul. 7 at 6:30 PM
$ENLV Equity Corporate Actions Alert #2026 - 473 Information Regarding the Reverse Stock Split, Par Value and CUSIP Number Change for Enlivex Ltd. (ENLV) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-473 Enlivex Ltd. (ENLV) will effect a one-for-fifteen (1-15) reverse split of its Ordinary Shares. The reverse stock split and change in par value from NIS 0.40 to NIS 6.00 will become effective on Thursday, July 9, 2026. In conjunction with the reverse split, the CUSIP number will change to M4130Y171.
1 · Reply
FST3
FST3 Jul. 7 at 2:36 PM
$ENLV - thank you for the cheap shares. Market cap of $110M, but Rain Tokens worth $1.2B....SMOKE AND MIRRORS BY THE SHORTS.
0 · Reply
Pacho_Unlimited1
Pacho_Unlimited1 Jul. 7 at 1:33 PM
$ENLV Well.... I did tell you....
1 · Reply